These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29682300)

  • 1. Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy.
    Murray JM
    J Virus Erad; 2018 Apr; 4(2):91-98. PubMed ID: 29682300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Mediated CD4 Depletion Induces Homeostatic CD4
    Kumar NA; McBrien JB; Carnathan DG; Mavigner M; Mattingly C; White ER; Viviano F; Bosinger SE; Chahroudi A; Silvestri G; Paiardini M; Vanderford TH
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir.
    Avalos CR; Abreu CM; Queen SE; Li M; Price S; Shirk EN; Engle EL; Forsyth E; Bullock BT; Mac Gabhann F; Wietgrefe SW; Haase AT; Zink MC; Mankowski JL; Clements JE; Gama L
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the impact of autologous neutralizing antibodies on viral rebound in postnatally SHIV-infected ART-treated infant rhesus macaques.
    Mainou E; Berendam SJ; Obregon-Perko V; Uffman EA; Phan CT; Shaw GM; Bar KJ; Kumar MR; Fray EJ; Siliciano JM; Siliciano RF; Silvestri G; Permar SR; Fouda GG; McCarthy J; Chahroudi A; Conway JM; Chan C
    bioRxiv; 2023 Sep; ():. PubMed ID: 37502921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.
    Hill AL; Rosenbloom DI; Goldstein E; Hanhauser E; Kuritzkes DR; Siliciano RF; Henrich TJ
    PLoS Pathog; 2016 Apr; 12(4):e1005535. PubMed ID: 27119536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
    Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
    Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
    J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.
    Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy.
    Wang S; Rong L
    J Theor Biol; 2014 Nov; 360():137-148. PubMed ID: 25016044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
    Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
    PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
    Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
    AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious Virus Persists in CD4
    Abreu CM; Veenhuis RT; Avalos CR; Graham S; Queen SE; Shirk EN; Bullock BT; Li M; Metcalf Pate KA; Beck SE; Mangus LM; Mankowski JL; Clements JE; Gama L
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31118264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure.
    Siliciano JD; Siliciano RF
    Annu Rev Pathol; 2022 Jan; 17():271-294. PubMed ID: 34736342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.
    Strongin Z; Micci L; Fromentin R; Harper J; McBrien J; Ryan E; Shenvi N; Easley K; Chomont N; Silvestri G; Paiardini M
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32350073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells.
    Soriano-Sarabia N; Bateson RE; Dahl NP; Crooks AM; Kuruc JD; Margolis DM; Archin NM
    J Virol; 2014 Dec; 88(24):14070-7. PubMed ID: 25253353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
    Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
    PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial.
    Alagaratnam J; Stöhr W; Hamlyn E; Porter K; Toombs J; Heslegrave A; Zetterberg H; Gisslén M; Underwood J; Schechter M; Kaleebu P; Tambussi G; Kinloch S; Miro JM; Kelleher AD; Babiker A; Frater J; Winston A; Fidler S;
    J Virus Erad; 2024 Jun; 10(2):100381. PubMed ID: 38988673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
    Hamlyn E; Ewings FM; Porter K; Cooper DA; Tambussi G; Schechter M; Pedersen C; Okulicz JF; McClure M; Babiker A; Weber J; Fidler S;
    PLoS One; 2012; 7(8):e43754. PubMed ID: 22952756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.